Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.020 +0.020 (+2.00%)

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pliant Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

In a landmark moment for respiratory medicine and biotechnology, United Therapeutics (NASDAQ:UTHR) announced late Monday, March 30, 2026, that its pivotal TETON-1 Phase 3 study for nebulized Tyvaso...

Via MarketMinute

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 04, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 27, 2025

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

June 27, 2025

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 05, 2025

Via Benzinga

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types ↗

March 17, 2025

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.

Via Benzinga

What's going on in today's after hours session ↗

March 10, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Pliant Therapeutics Drops IPF Drug Trial After Review, Analyst Flags Uncertain Future ↗

March 04, 2025

Pliant Therapeutics ends its Phase 2b IPF trial for bexotegrast, prompting a Needham downgrade to Hold due to limited catalysts and pipeline challenges.

Via Benzinga

This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday ↗

March 04, 2025

Via Benzinga

Get insights into the top gainers and losers of Monday's after-hours session. ↗

March 03, 2025

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Here are the top movers in Monday's session. ↗

March 03, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder ↗

March 03, 2025

Pliant Therapeutics discontinued its BEACON-IPF trial for bexotegrast due to safety concerns but observed early efficacy. The company plans further data analysis.

Via Benzinga

Let's take a look at the stocks that are in motion in today's session. ↗

March 03, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Which stocks are gapping on Monday? ↗

March 03, 2025

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Unusual volume stocks in Wednesday's session ↗

February 12, 2025

On Wednesday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

Which stocks are experiencing notable movement on Monday? ↗

February 10, 2025

Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

Crude Oil Rises Sharply; Manhattan Associates Shares Slide ↗

February 10, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 10, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Nasdaq Surges 1%; ON Semiconductor Shares Plunge Following Earnings Miss ↗

February 10, 2025

Via Benzinga

This Illumina Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

February 10, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

February 10, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Dow Gains 100 Points; McDonald's Shares Rise After Q4 Results ↗

February 10, 2025

Via Benzinga

Topics Stocks

Monday's pre-market session: top gainers and losers ↗

February 10, 2025

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Via Chartmill

Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues ↗

February 10, 2025

Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed bexotegrast reduced lung collagen.

Via Benzinga

Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

February 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

February 10, 2025

Via Benzinga

Why BP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket ↗

February 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 19, 2024

Via Benzinga

Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

December 13, 2024

Via Benzinga

PLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024 ↗

August 07, 2024

PLRX stock results show that Pliant Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.